Amyloid-β (Aβ) pathology is one of the earliest detectable brain changes in Alzheimer's
disease (AD) pathogenesis. The overall load and spatial distribution of brain Aβ can be …

Deposition of amyloid and tau pathology can be quantified in vivo using positron emission
tomography (PET). Accurate longitudinal measurements of accumulation from these images …

Current PET datasets are becoming larger, thereby increasing the demand for fast and
reproducible processing pipelines. This paper presents a freely available, open source …

Background Biomarkers for amyloid, tau, and neurodegeneration (ATN) have predictive
value for clinical progression, but it is not clear how individuals move through these stages …

Since the development of amyloid tracers for PET imaging, there has been interest in
quantifying amyloid burden in the brains of patients with Alzheimer disease. Quantitative …

Optimal pharmacokinetic models for quantifying amyloid beta (Aβ) burden using both [18 F]
flutemetamol and [18 F] florbetaben scans have previously been identified at a region of …

Background Dynamic PET imaging studies provide accurate estimates of specific binding,
but also measure the relative tracer delivery (R1), which is a proxy for relative cerebral blood …

Objectives This study aimed to explore the potential of full dynamic PET kinetic analysis in
assessing amyloid binding and perfusion in the cardiac region using 18 F-Florbetapir PET …

Purpose The role of cerebral blood flow (CBF) in the early stages of Alzheimer's disease is
complex and largely unknown. We investigated cross-sectional and longitudinal …

Purpose To determine thresholds for amyloid beta pathology and evaluate associations with
longitudinal memory performance with the aim to identify a grey zone of early amyloid beta …